Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen nEUPOGEN (filgrastim — Neutropenia, legacy standalone disclosure) — U.S. product sales ($M) ($M)
Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail
Latest, FY2022
87
Period ended Dec 31, 2022
Change on a year earlier
-13.9%
101 in FY2021
History
6 years
Since FY2017
Sources
6
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | NEUPOGEN (filgrastim — Neutropenia, legacy standalone disclosure) — U.S. product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2022 | Dec 31, 2022 | 87 | -13.9% | Form 10-K (amgn-20221231.htm, filed 2023-02-09) ↗ |
| FY2021 | Dec 31, 2021 | 101 | -29.9% | Form 10-K (amgn-20211231.htm, filed 2022-02-16) ↗ |
| FY2020 | Dec 31, 2020 | 144 | -19.1% | Form 10-K (amgn-20201231.htm, filed 2021-02-09) ↗ |
| FY2019 | Dec 31, 2019 | 178 | -20.2% | Form 10-K (amgn-12312019x10kq42019.htm, filed 2020-02-12) ↗ |
| FY2018 | Dec 31, 2018 | 223 | -39.6% | Form 10-K (amgn-12312018x10kq42018.htm, filed 2019-02-13) ↗ |
| FY2017 | Dec 31, 2017 | 369 | – | Form 10-K (amgn-12312017x10k.htm, filed 2018-02-13) ↗ |
Cite this data
StockData. (2026). Amgen NEUPOGEN (filgrastim — Neutropenia, legacy standalone disclosure) — U.S. product sales ($M) ($M), annual FY2017–FY2022 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod_neupogen_us
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.